

ASX ANNOUNCEMENT

RESULTS OF 2017 Extraordinary General Meeting

12th April 2017: Analytica Limited (ASX: ALT) advises that all resolutions were passed by a show of hands.

Proxy votes received were as follows:

Resolution Number	Resolution Name	For resolution	Open votes held by the Chair (for resolution)	Against resolution	Abstain from voting
1	Approval for the issue of Shares to entities associated with Dr Michael Monsour (Chairman)	732,472,045 92.8%	7,886,136 1.0%	49,236,160 6.2%	140,912 -
2	Approval for the issue of Shares to entities associated with Mr Ross Mangelsdorf (Executive Director)	1,181,586,763 95.4%	7,886,136 0.6%	49,136,729 4.0%	140,912 -
3	Ratification of General Placement	919,851,001 94.3%	10,180,536 1.0%	45,960,572 4.7%	40,912 -
4	Ratification of Placement	1,234,466,370 95.8%	8,139,547 0.6%	46,674,088 3.6%	41,912 -
5	Approval of placement to Inov8 LLC	958,869,275 94.5%	10,904,974 1.1%	44,991,096 4.4%	803,363 -
6	Approval of Employee Share Option Plan	1,226,587,885 96.9%	10,751,563 0.8%	28,727,070 2.3%	23,255,399 -

Bryan Dulhunty
Company Secretary

About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.



PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the USA.